Structures by: Vyas K.
Total: 33
C14H14N2O2
C14H14N2O2
Chemical Communications (Cambridge, United Kingdom) (2007) 19 1966-1968
a=23.78(1)Å b=4.560(3)Å c=11.134(7)Å
α=90° β=90° γ=90°
C8H12N2,2(C7H6O3)
C8H12N2,2(C7H6O3)
Chemical Communications (Cambridge, United Kingdom) (2007) 23 2375-2377
a=13.039(7)Å b=7.401(4)Å c=22.560(12)Å
α=90° β=102.440(5)° γ=90°
C8H12N2,2(C7H6O3)
C8H12N2,2(C7H6O3)
Chemical Communications (Cambridge, United Kingdom) (2007) 23 2375-2377
a=10.5495(11)Å b=10.3154(9)Å c=10.2205(11)Å
α=90° β=109.904(4)° γ=90°
1,2-bis(4-pyridinium)ethane saccharinate (1:2)
C12H14N2,2(C7H4NO3S)
CrystEngComm (2008) 10, 8 996
a=7.5770(8)Å b=11.0722(13)Å c=15.260(2)Å
α=90° β=90.809(11)° γ=90°
1,2-bis(4-pyridinium)ethylene saccharinate (1:2)
C12H12N2,2(C7H4NO3S)
CrystEngComm (2008) 10, 8 996
a=13.161(2)Å b=5.251(2)Å c=18.590(12)Å
α=90° β=106.828(3)° γ=90°
C4H12N2,2(C7H4NO3S)
C4H12N2,2(C7H4NO3S)
CrystEngComm (2008) 10, 8 996
a=11.1261(10)Å b=9.3971(8)Å c=9.6281(10)Å
α=90.0000° β=99.489(4)° γ=90.0000°
1,4-Dimethylpiperazinium saccharinate (1:2)
C6H16N2,2(C7H4NO3S)
CrystEngComm (2008) 10, 8 996
a=7.973(2)Å b=15.413(3)Å c=9.293(2)Å
α=90° β=104.555(10)° γ=90°
2,2'-dipyridiniumamine saccharinate (1:1)
C10H10N3,C7H4NO3S
CrystEngComm (2008) 10, 8 996
a=9.635(2)Å b=13.385(4)Å c=14.149(3)Å
α=105.658(3)° β=91.773(2)° γ=110.444(2)°
C16H24N5O,C6H4NO2,CH4O
C16H24N5O,C6H4NO2,CH4O
CrystEngComm (2008) 10, 3 283
a=9.7496(9)Å b=19.3384(12)Å c=13.2982(10)Å
α=90.0000° β=103.445(3)° γ=90.0000°
C16H23N5O
C16H23N5O
CrystEngComm (2008) 10, 3 283
a=7.395(4)Å b=11.218(6)Å c=20.202(10)Å
α=90.0000° β=90.0000° γ=90.0000°
C16H25N5O2
C16H25N5O2
CrystEngComm (2008) 10, 3 283
a=7.111(3)Å b=10.857(5)Å c=23.106(10)Å
α=90.0000° β=93.241(4)° γ=90.0000°
C24H24Cl3NO2Ru
C24H24Cl3NO2Ru
Dalton transactions (Cambridge, England : 2003) (2018) 47, 2 517-527
a=16.8227(12)Å b=11.3329(8)Å c=25.1614(17)Å
α=90° β=90° γ=90°
C24H27ClO3Ru
C24H27ClO3Ru
Dalton transactions (Cambridge, England : 2003) (2018) 47, 2 517-527
a=9.328(5)Å b=11.490(6)Å c=21.330(10)Å
α=90° β=90° γ=90°
C8H12N2,2(C7H6O3)
C8H12N2,2(C7H6O3)
Chemical Communications (Cambridge, United Kingdom) (2007) 23 2375-2377
a=10.5495(11)Å b=10.3154(9)Å c=10.2205(11)Å
α=90° β=109.904(4)° γ=90°
C8H12N2,2(C7H6O3)
C8H12N2,2(C7H6O3)
Chemical Communications (Cambridge, United Kingdom) (2007) 23 2375-2377
a=13.039(7)Å b=7.401(4)Å c=22.560(12)Å
α=90° β=102.440(5)° γ=90°
C14H14N2O2
C14H14N2O2
Chemical Communications (Cambridge, United Kingdom) (2007) 19 1966-1968
a=23.78(1)Å b=4.560(3)Å c=11.134(7)Å
α=90° β=90° γ=90°
Venlafaxine hydrocloride
C17H28NO2,Cl
Acta Crystallographica Section E (2002) 58, 10 o1072-o1074
a=5.797(6)Å b=26.074(7)Å c=11.722(3)Å
α=90° β=100.72(5)° γ=90°
7-nitro-1,2,3a,4-tetrahydrobenzo[b][1,3] oxazolo [3,2-d] oxazine.
C10H10N2O4
Acta Crystallographica Section E (2003) 59, 3 o360-o362
a=12.164(2)Å b=22.079(4)Å c=7.373(2)Å
α=90° β=100.86(2)° γ=90°
C21H20F3N3O5S
C21H20F3N3O5S
Acta Crystallographica Section E (2003) 59, 11 o1731-o1732
a=10.4490(8)Å b=12.0126(8)Å c=9.2196(9)Å
α=111.068(6)° β=94.851(7)° γ=86.328(6)°
Gemcitabine Hydrochloride
C9H12F2N3O41,Cl1
Acta Crystallographica Section E (2003) 59, 10 o1435-o1437
a=11.4680(7)Å b=15.5987(9)Å c=6.706(2)Å
α=90° β=90° γ=90°
8-methoxy-1,3-dimethyl-12-thioxopyrido[1',2':3,4]- imidazo[1,2-a][1,3]benzimidazol-2(12H)-one
C16H13N3O2S
Acta Crystallographica Section C (1999) 55, 12 IUC9900162
a=7.002(2)Å b=18.442(5)Å c=11.443(2)Å
α=90° β=102.72(2)° γ=90°
4-[4-Acetyloxy-3,5,6-trimethyl-1-[4-nitrobenzoyl]oxy-2-yl]butan-2-one
C22H23NO7
Acta Crystallographica Section C (1999) 55, 12 IUC9900160
a=12.1860(10)Å b=8.7763(9)Å c=20.4128(9)Å
α=90° β=104.593(4)° γ=90°
Celecoxib
C17H14F3N3O2S
Acta Crystallographica Section C (1999) 55, 12
a=10.136(5)Å b=16.778(6)Å c=5.066(6)Å
α=97.62(7)° β=100.65(6)° γ=95.95(4)°
Troglitazone
C24H27NO5S
Acta Crystallographica Section C (1999) 55, 3 411-413
a=16.239(3)Å b=11.717(3)Å c=11.627(4)Å
α=90° β=93.69(2)° γ=90°
C25H28N2O4
C25H28N2O4
Acta Crystallographica Section C (1999) 55, 7 IUC9900077
a=11.938(8)Å b=24.421(5)Å c=7.8395(12)Å
α=90° β=90° γ=90°
C23H38N2O2,C1H4O1
C23H38N2O2,C1H4O1
Acta Crystallographica Section C (1999) 55, 9 IUC9900105
a=11.607(2)Å b=20.097(5)Å c=10.449(4)Å
α=90° β=90° γ=90°
C22H25Cl1N5O21,C4H3O41,2.5H2O1
C22H25Cl1N5O21,C4H3O41,2.5H2O1
Acta Crystallographica Section C (1999) 55, 9 IUC9900104
a=6.676(5)Å b=24.324(7)Å c=17.660(10)Å
α=90° β=95.87(6)° γ=90°
Sparfloxacin
C19H22F2N4O3,3H2O1
Acta Crystallographica Section C (2000) 56, 3 e115-e116
a=11.850(3)Å b=10.913(4)Å c=17.506(2)Å
α=90° β=107.760(10)° γ=90°
Lansoprazole
C16H14F3N3O2S
Acta Crystallographica Section C (2000) 56, 12 e572-e573
a=15.8700(10)Å b=7.3481(8)Å c=14.2620(10)Å
α=90.00° β=102.032(5)° γ=90.000°
4-(4-methylsulfonylphenyl)-3-phenyl-2,5-dihydro-2-furanone
C17H14O4S
Acta Crystallographica Section C (2000) 56, 2 e68-e68
a=11.374(2)Å b=11.3740Å c=22.939(3)Å
α=90° β=90° γ=90°
C19H30N4O4,H2O
C19H30N4O4,H2O
Journal of Organic Chemistry (2004) 69, 2181-2184
a=9.7224(8)Å b=10.4293(9)Å c=10.3489(9)Å
α=90.00° β=104.695(2)° γ=90.00°
C18H19NO2S
C18H19NO2S
Journal of Organic Chemistry (2007) 72, 8547-8550
a=9.173(3)Å b=9.411(3)Å c=10.685(3)Å
α=66.370(12)° β=69.458(12)° γ=73.57(1)°
C20H21NO2S
C20H21NO2S
Journal of Organic Chemistry (2007) 72, 8547-8550
a=8.950(5)Å b=10.125(6)Å c=10.704(5)Å
α=90.434(4)° β=94.258(8)° γ=111.215(6)°